{
    "clinical_study": {
        "@rank": "67273", 
        "arm_group": [
            {
                "arm_group_label": "IncobotulinumtoxinA (Xeomin) (100 Units)", 
                "arm_group_type": "Experimental", 
                "description": "Main period (1 treatment cycle): Subjects to receive 100 Units.\nExtension period (3 treatment cycles): Subjects to receive 100 Units per treatment cycle.\nMode of administration: Four injections per treatment cycle (parotid and submandibular glands, bilateral)"
            }, 
            {
                "arm_group_label": "IncobotulinumtoxinA (Xeomin) (75 Units)", 
                "arm_group_type": "Experimental", 
                "description": "Main period (1 treatment cycle): Subjects to receive 75 Units.\nExtension period (3 treatment cycles): Subjects to receive 75 Units per treatment cycle.\nMode of administration: Four injections per treatment cycle (parotid and submandibular glands, bilateral)"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Main period (1 treatment cycle): Subjects to receive placebo injection.\nExtension period (3 treatment cycles): Subjects will be randomized to receive either 75 or 100 Units IncobotulinumtoxinA per treatment cycle.\nMode of administration: Four injections per treatment cycle (parotid and submandibular glands, bilateral)"
            }
        ], 
        "brief_summary": {
            "textblock": "The objective of this study is to investigate the efficacy and safety of two different dose\n      levels of NT 201 (75 U or 100 U per cycle), compared with placebo, in reducing the salivary\n      flow rate, and the severity and frequency of chronic troublesome sialorrhea that occurs as a\n      result of various neurological conditions in adult subjects."
        }, 
        "brief_title": "Clinical Study to Investigate the Efficacy and Safety of Two Dose Levels of NT 201 Versus Placebo in Treating Chronic Troublesome Sialorrhea in Various Neurological Conditions", 
        "completion_date": {
            "#text": "July 2016", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Chronic Troublesome Sialorrhea", 
            "Parkinson's Disease", 
            "Post-stroke", 
            "Traumatic Brain Injury"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Parkinson Disease", 
                "Sialorrhea", 
                "Stroke", 
                "Brain Injuries", 
                "Wounds and Injuries"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Documented diagnosis of the basic neurological condition associated with sialorrhea\n             (as above, (i), (ii) or (iii); with onset at least 6 months before screening).\n\n          -  Chronic troublesome sialorrhea (for at least 3 months) at screening, defined as the\n             presence of all of the following, at screening and at baseline and for at least the 3\n             months before screening (where retrospective response to questionnaires is\n             impossible, a statement of equivalent severity will suffice):\n\n               1. A Drooling Severity and Frequency Scale [DSFS] sum score of at least 6 points\n                  and\n\n               2. A score of at least 2 points for each item of the DSFS and\n\n               3. A score of at least 3 points on the modified Radboud Oral Motor Inventory for\n                  Parkinson's Disease [mROMP], Section 'III Drooling', Item A).\n\n          -  A score of at most 2 points on the mROMP Section 'II Swallowing Symptoms' Item A) and\n             a score of at most 3 points on Item C), at screening and at baseline.\n\n        Exclusion Criteria:\n\n          -  Non-neurological secondary causes of sialorrhea.\n\n          -  Unstable concomitant medication influencing sialorrhea (such as anticholinergics for\n             the treatment of parkinsonism; dosages of these medications must have been stable for\n             at least 4 weeks before study entry and must be planned to remain stable during the\n             course of the study.\n\n          -  Recent (i.e., four weeks) drug treatment for sialorrhea.\n\n          -  History of recurrent aspiration pneumonia.\n\n          -  Extremely poor dental/oral condition.\n\n          -  Recent (i.e., one year for sialorrhea, 14 weeks for other indications) treatment with\n             - or known hypersensitivity to - Botulinum toxin, or known hypersensitivity to any\n             ingredient of the study preparation.\n\n          -  Recent (i.e., four weeks) changes in anti-parkinsonian medication.\n\n          -  Previous or planned surgery or irradiation to control sialorrhea."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "180", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 18, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02091739", 
            "org_study_id": "MRZ60201_3090_1", 
            "secondary_id": "2012-005539-10"
        }, 
        "intervention": [
            {
                "arm_group_label": "IncobotulinumtoxinA (Xeomin) (100 Units)", 
                "description": "Active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).", 
                "intervention_name": "IncobotulinumtoxinA (100 Units)", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Xeomin", 
                    "NT 201", 
                    "Botulinum toxin type A (150 kiloDalton), free from complexing proteins"
                ]
            }, 
            {
                "arm_group_label": "IncobotulinumtoxinA (Xeomin) (75 Units)", 
                "description": "Active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).", 
                "intervention_name": "IncobotulinumtoxinA (75 Units)", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Xeomin", 
                    "NT 201", 
                    "Botulinum toxin type A (150 kiloDalton), free from complexing proteins"
                ]
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Botulinum Toxins, Type A", 
                "Botulinum Toxins"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "May 23, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Gera", 
                        "country": "Germany", 
                        "zip": "07551"
                    }, 
                    "name": "Merz Investigational Site #049335"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Haag i.OB", 
                        "country": "Germany", 
                        "zip": "83527"
                    }, 
                    "name": "Merz Investigational Site #049337"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Westerstede", 
                        "country": "Germany", 
                        "zip": "26655"
                    }, 
                    "name": "Merz Investigational Site #049336"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Wolfach", 
                        "country": "Germany", 
                        "zip": "77709"
                    }, 
                    "name": "Merz Investigational Site #049333"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lodz", 
                        "country": "Poland", 
                        "zip": "90-130"
                    }, 
                    "name": "Merz Investigational Site #048022"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sandomierz", 
                        "country": "Poland", 
                        "zip": "27-600"
                    }, 
                    "name": "Merz Investigational Site #048075"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "Germany", 
                "Poland"
            ]
        }, 
        "number_of_arms": "3", 
        "official_title": "Prospective, Randomized, Double-blind, Placebo-controlled, Parallel-group Multicenter Study, With an Extension Period of Dose-blinded Active Treatment, to Investigate the Efficacy and Safety of Two Dose Levels of NT 201 in Treating Chronic Troublesome Sialorrhea in Various Neurological Conditions", 
        "overall_contact": {
            "email": "clinicaltrials@merz.de", 
            "last_name": "Public Disclosure Manager"
        }, 
        "overall_official": {
            "affiliation": "Merz Pharmaceuticals GmbH", 
            "last_name": "Merz Medical Expert", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "Germany: Federal Institute for Drugs and Medical Devices", 
                "Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "April 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "uSFR: weighing of dental rolls soaked with saliva over 5 minutes; procedure repeated after 30 minutes. The reduction of measured weight over the study relates to improvement of sialorrhea.", 
                "measure": "Unstimulated salivary flow rate (uSFR)", 
                "safety_issue": "No", 
                "time_frame": "Baseline to week 4"
            }, 
            {
                "description": "This is a co-primary outcome measure. The GICS is used to measure the investigator's impression of change due to treatment. The response option is a common 7-point Likert scale that ranges from -3 = very much worse to +3 = very much improved.\nIf the subject is not able to answer: carer's GICS entry.", 
                "measure": "Subject's Global Impression of Change Scale (GICS) entry", 
                "safety_issue": "No", 
                "time_frame": "Week 4"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02091739"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Unstimulated salivary flow rate", 
                "safety_issue": "No", 
                "time_frame": "Baseline up to week 12"
            }, 
            {
                "measure": "Subject's Global Impression of Change Scale (GICS) entry", 
                "safety_issue": "No", 
                "time_frame": "Baseline up to week 12"
            }
        ], 
        "source": "Merz Pharmaceuticals GmbH", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Merz Pharmaceuticals GmbH", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}